Form 4: Denali Therapeutics Director Jay Flatley Receives Equity Grants

Director Jay Flatley was granted 6,408 restricted stock units and 19,226 stock options as part of annual compensation for his role on the board.

Summary

• Jay T. Flatley, a member of the Board of Directors, received 6,408 Restricted Stock Units (RSUs) on June 3, 2026.
• Flatley was also granted 19,226 stock options with an exercise price of $19.66 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on the earlier of the one-year anniversary of the grant or the day before the next annual meeting of stockholders.
• Following these transactions, the reporting person directly owns 22,628 shares of common stock, which includes the newly granted unvested RSUs.
• The reporting person maintains a significant indirect interest in 336,313 shares held by The Flatley Family Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative filing. While it involves the issuance of new shares, it confirms the continued commitment and alignment of an experienced director.

Positives

• Director compensation is heavily weighted toward equity, aligning board interests with those of long-term shareholders.
• The reporting person maintains a substantial indirect stake of 336,313 shares, indicating a high level of skin in the game.
• The stock options have a ten-year term, expiring in 2036, suggesting a long-term horizon for value creation.

Negatives

• The issuance of new RSUs and options represents a minor dilutive event for existing shareholders.
• The exercise price of $19.66 sets a baseline that the stock must exceed for the options to hold intrinsic value.

Risks

• The value of the equity awards is entirely dependent on the market performance of DNLI common stock.
• If the director leaves the board before the one-year vesting period, the awards may not fully vest depending on the terms of the plan.

Future Outlook

The equity grants ensure the director remains incentivized to oversee the company's strategic direction through the 2027 annual meeting of stockholders.

Management Comments

• The RSUs represent a contingent right to receive one share of common stock for each unit upon vesting.
• The options and RSUs vest fully on the one-year anniversary of the grant or the day preceding the next annual meeting.

Industry Context

StockSavvy.ai notes that Denali Therapeutics' use of equity-based compensation for directors is consistent with industry standards in the biotechnology sector, where cash is often preserved for research and development while board members are incentivized through long-term stock performance.

Comparison to Industry Standards

• The grant size is typical for a mid-to-large cap biotechnology company board member.
• Vesting schedules of one year for director grants are standard across the NASDAQ Biotechnology Index.
• The ten-year option term is a standard duration for incentive stock options in the healthcare sector.

Corporate Governance

Related Party Transactions

• The reporting person holds 336,313 shares indirectly through The Flatley Family Trust.

Stakeholder Impact

• Shareholders may experience minor dilution from the 25,634 total units granted.
• The board maintains stability with the continued participation of Jay Flatley.

Next Steps

• Vesting of the RSUs and options on or around June 3, 2027.
• Potential future Form 4 filings if the director chooses to sell shares or exercise options.

Key Dates

Recommendation

This is a routine compensation-related filing that does not signal a change in company fundamentals or a significant shift in insider sentiment beyond standard annual grants.

Keywords

Denali Therapeutics, DNLI, Insider Trading, Form 4, Jay Flatley, Stock Options, Restricted Stock Units, Biotechnology, Director Compensation